Rezolute Inc
NASDAQ:RZLT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Rezolute Inc
Operating Income
Rezolute Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Rezolute Inc
NASDAQ:RZLT
|
Operating Income
-$89.9m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-22%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$20.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$11.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$16.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$3.9B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
12%
|
|
Rezolute Inc
Glance View
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 26 full-time employees. The company went IPO on 2011-12-23. The firm's lead clinical asset, RZ358, is an antibody therapy in Phase II b development as a potential treatment for Congenital Hyperinsulinism (CHI), an ultra-rare pediatric genetic disorder. Its second clinical asset, RZ402, is a selective and potent Plasma Kallikrein Inhibitor (PKI) being developed as a potential oral therapy for the chronic treatment of Diabetic Macular Edema (DME), is in Phase I development. The clinical study conducting by the Company is called RIZE - An open-label multiple-dose study of RZ358 in Patients with Congenital Hyperinsulinism.
See Also
What is Rezolute Inc's Operating Income?
Operating Income
-89.9m
USD
Based on the financial report for Dec 31, 2025, Rezolute Inc's Operating Income amounts to -89.9m USD.
What is Rezolute Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-22%
Over the last year, the Operating Income growth was -23%. The average annual Operating Income growth rates for Rezolute Inc have been -24% over the past three years , -36% over the past five years , and -22% over the past ten years .
